

Maria Chiara Finazzi, MD

Personal data

Name: Maria Chiara Finazzi
Date and place of birth: 09/01/1983, Trescore Balneario, Italy
Citizenship: Italiana
Work address: USC Ematologia, AO Papa Giovanni XXIII,
Piazza OMS, 1 24127 Bergamo, Italy
Phone: +39 035 2673637
E-mail: mc.finazzi@hotmail.it



Education

From June 2009: Fellow at the Postgraduate school of Hematology, Department of Hematology, University of Milano-Bicocca

March 2009: medical licence n° 6623, Bergamo

October 2008: MD Degree 110/110 magna cum laude at the University of Brescia

Postgraduate in Hematology, University of Milan - Bicocca – July 2014

Research experience

September 2007 - February 2009: fellow in the Laboratory “G. Lanzani- Laboratorio di terapia cellulare e genica”, Hematology Department, AO Ospedali Riuniti di Bergamo

Current Position

Clinical research assistant in Hematology and Bone Marrow Transplant Unit, A.O. “Papa Giovanni XXIII” involved in management of patients with chronic myeloproliferative diseases enrolled in clinical trials.

Publications

1: Finazzi MC, Carobbio A, Cervantes F, Isola IM, Vannucchi AM, Guglielmelli P, Rambaldi A, Finazzi G, Barosi G, Barbui T. CALR mutation, MPL mutation and triple negativity identify patients with the lowest vascular risk in primary myelofibrosis. *Leukemia*. 2015 May;29(5):1209-10.

2: Golay J, D'Amico A, Borleri G, Bonzi M, Valgardsdottir R, Alzani R, Cribioli S, Albanese C, Pesenti E, Finazzi MC, Quaresmini G, Nagorsen D, Introna M, Rambaldi A. A novel method using blinatumomab for efficient, clinical-grade expansion of polyclonal T cells for adoptive immunotherapy. *J Immunol*. 2014 Nov 1;193(9):4739-47.

3: Martinelli I, De Stefano V, Carobbio A, Randi ML, Santarossa C, Rambaldi A, Finazzi MC, Cervantes F, Arellano-Rodrigo E, Rupoli S, Canafoglia L, Tieghi A, Facchini L, Betti S, Vannucchi AM, Pieri L, Cacciola R, Cacciola E, Cortelezzi A, Iurlo A, Pogliani EM, Elli EM, Spadea A, Barbui T. Cerebral vein thrombosis in patients with Philadelphia-negative myeloproliferative neoplasms. An European Leukemia Net study. *Am J Hematol*. 2014 Nov;89(11)

4: Lussana F, Rambaldi A, Finazzi MC, van Biezen A, Scholten M, Oldani E, Carobbio A, Iacobelli S, Finke J, Nagler A, Volin L, Lamy T, Arnold R, Mohty M, Michallet M, de Witte T, Olavarria E, Kröger N. Allogeneic hematopoietic stem cell transplantation in patients with polycythemia vera or essential thrombocythemia transformed to myelofibrosis or acute myeloid leukemia: a report from the MPN Subcommittee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation. *Haematologica*. 2014 May;99(5):916-21.

5: Finazzi G, Vannucchi AM, Martinelli V, Ruggeri M, Nobile F, Specchia G, Pogliani EM, Olimpieri OM, Fioritoni G, Musolino C, Cilloni D, Sivera P, Barosi G, Finazzi MC, Di Tollo S, Demuth T, Barbui T, Rambaldi A. A phase II study of Givinostat in combination with hydroxycarbamide in patients with polycythemia vera unresponsive to hydroxycarbamide monotherapy. *Br J Haematol*. 2013 Jun;161(5):688-94.

6: Barbui T, Finazzi MC, Finazzi G. Front-line therapy in polycythemia vera and essential thrombocythemia. *Blood Rev*. 2012 Sep;26(5):205-11.